A weekly report on the drug and biologic approvals the U.S. Food and Drug Administration published this week, read from the FDA's own application records and approved labels. COMPLETENESS IS THE PRODUCT: every supplied application gets its own spoken segment, including the routine ones and the ones whose label was not published yet. A listener must be able to treat the episode as the week's full record. If there is more material than time, compress how much you say about each application — never drop one, and never merge two applications into one segment unless the documents themselves show they share an approval letter. If you state a count of the week's approvals, it must equal the number of supplied documents; do not total up only the ones you found interesting. Name every application explicitly in its own segment: the brand name, the applicant, and the application number, spoken aloud. This is not optional for the thin ones — an application whose label has not been published yet is reported by NAME with the label noted as pending, never as an anonymous 'seventh entry'. Two applications may share one segment ONLY when the documents show they share an approval letter; a shared gap in our own record — both missing a label, both brief — is never a reason to group them. Reaching the right total while leaving a product unnamed is still an incomplete episode. Attribute to the FDA's record and the approved label — never to 'the brief', 'the supplied documents', or 'the materials'. The listener has no idea what those are. Say nothing about a company's size, prominence, market position, reputation or familiarity — not 'a major pharmaceutical company', not 'a household name', not 'a small biotech', not 'an industry giant'. The documents give you the applicant's name and nothing more about it, so the name is all you may say. The same limit applies to characterizing a product as significant, notable, long-awaited or minor: report what the record states about it and let the listener weigh it. Covering 2026-07-27 – 2026-08-02.
In this episode:
• NDA 219990 — Gwyn Lo (VIATRIS SPECIALTY) — FDA approval, 2026-07-28 — https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219990
• NDA 220381 — NDA 220381 (FRESENIUS KABI USA LLC) — FDA approval, 2026-07-29 — https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220381
• NDA 221094 — Qlonilik (CMP DEV LLC) — FDA approval, 2026-07-29 — https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=221094
Create your own podcast — free. Turn any topic into a research-backed, multi-host episode like this one — no card needed: https://demades.ai/studio?studio=1&topic=FDA+Approvals+July+27%E2%80%93August+2%3A+One+Label%2C+Two+Pending&utm_source=rss&utm_campaign=rss